Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990

COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (Mpro) inhibitor bearing a unique trifluoromethoxymethyl ketone warhead. Here, we broadly evaluate its pan-coronavirus target engagement, antiviral breadth, and pharmacologic differentiation. Across a reporter panel of…

We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.

Read the original at biorxiv.org →

More in Health & Medicine

More from Thursday 1 October →